Company Overview
Anixa Biosciences, Inc. operates as a biotechnology entity dedicated to developing therapies and vaccines that address critical unmet needs within the oncology sector. The company's therapeutic programs include the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, which represents a novel form of chimeric antigen receptor technology aimed at treating cancer. This business falls under the Healthcare sector and specifically within the Biotechnology industry, positioning the firm in a high-risk, high-reward environment where companies often prioritize long-term R&D over immediate profitability. The company currently maintains a market capitalization of $85.50M and employs a workforce of 4 individuals, indicating a very small-scale operation typical of early-stage biotechnology firms. The combination of a market cap under $100 million and a minimal employee base suggests that Anixa Biosciences is in the nascent stages of commercialization, likely relying on external capital to fund its research and development efforts before achieving significant revenue generation or market dominance.
Financial Health
The company reports a net income of $-10,308,000 for the trailing twelve months, while its revenue and EBITDA figures are listed as not available, a common scenario for biotechnology companies in the pre-revenue or pre-commercialization phase where expenses significantly outpace income. The absence of reported revenue alongside a substantial net loss of over $10 million reveals a cost structure driven almost entirely by research and development expenditures rather than cost of goods sold or operating overhead. Free cash flow stands at $-3,492,375, indicating that the company is burning cash at a rate that requires continuous financing to sustain operations and advance its clinical programs. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which is mathematically consistent with a lack of revenue but highlights the absence of profitability in any form. On the balance sheet, the company holds $14.20M in cash against $193,000 in debt, creating a capital position that is heavily cash-weighted rather than leveraged, though the debt-to-equity ratio is reported as 1.39, suggesting potential accounting complexities or specific equity definitions used in the calculation. The current ratio is an exceptionally high 12.18, which indicates strong short-term liquidity relative to current liabilities, providing a significant buffer against immediate financial obligations despite the lack of operating cash flow. Return on equity is -68.1% and return on assets is -40.4%, metrics that clearly demonstrate that management has not yet generated positive returns on the capital invested in the business.
Valuation Assessment
Trailing P/E and forward P/E ratios are presented as N/A and -6.89 respectively, where the negative forward P/E reflects the company's expected losses and the lack of trailing earnings due to its current financial status. The price-to-book ratio is 5.65, indicating that the market values the company at a significant premium over its book value, likely driven by the potential intellectual property and clinical pipeline rather than current tangible assets. Price-to-sales ratio and EV/EBITDA are both listed as N/A, suggesting that traditional valuation multiples based on sales or earnings are not applicable until the company generates measurable revenue and earnings. The stock has traded within a 52-week range between a high of $5.46 and a low of $2.33, and without a specific current price provided in the available facts, the valuation relative to this historical range cannot be numerically calculated but the trading band defines the historical volatility and investor sentiment. The beta value is 0.52, which indicates that the stock's price volatility is roughly half that of the broader market, suggesting it moves less aggressively than the S&P 500 despite being in a volatile biotechnology sector.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the fact that the company has not yet established a consistent historical revenue stream to calculate growth rates. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders, a standard practice for biotechnology firms that must reinvest all available capital into research and development to advance their clinical trials. The overall growth and income profile is currently defined by the absence of commercial income and growth metrics, with the company's value derived entirely from its future potential rather than current financial performance or shareholder distributions.